The objective of this study is to evaluate the effects of
solifenacin on double-J
stent-related symptoms following uncomplicated ureterosocpic
lithotripsy (URSL). A total of 70 patients who underwent double-J ureteral
stent insertion following URSL were consecutively recruited and received
solifenacin postoperatively. Another 70 age- and sex-matched subjects without
solifenacin therapy were enrolled as a control group. The clinical data including stone and
stent characteristics were collected. All subjects completed the brief-form Ureteral Symptom Score Questionnaire (Chinese-version) to assess the
lower urinary tract symptoms,
stent-related body
pain and
hematuria 2 weeks after operation. The severity of
stent-related symptoms was compared between two groups. The mean age was 53.8 in
solifenacin group and 53.4 years in the control group (p = 0.87). The stone characteristics,
stent size, position and curl completeness were similar in both groups. Compared to the control group,
solifenacin group had significantly lower total symptom score, urgency and
urge incontinence scores. As for
stent-related body
pain,
solifenacin group had significantly less flank, abdominal, urethral
pain and
hematuria scores (all p < 0.05). The
solifenacin versus control group showed significant benefits in
lower urinary tract symptoms,
stent-related
pain and
hematuria in both genders (all p < 0.05). Four subjects encountered minor adverse events (5.7 %) and one had
urinary retention (1.4 %) in
solifenacin group. For patients undergoing URSL and double-J
stent indwelling, postoperative
solifenacin use was effective and well-tolerated for the treatment of
lower urinary tract symptoms,
stent-related body
pain and
hematuria irrespective of genders.